OneSource Specialty Pharma Share Price

  • 1,846.60-0.41 (-0.03%)
  • Volume: 98,201
  • Closed
  • Last Updated On: 16 Oct, 2025, 03:31 PM IST
High: "2529.00",Open: "2480.25",Low: "2417.00",
Loading...
OneSource Specialty Pharma Share Price
  • 1,846.60-0.41 (-0.03%)
  • Volume: 98,201
Advertisment

Key Metrics

PE Ratio
(x)
-1,676.23
EPS - TTM
(₹)
-1.10
MCap
(₹ Cr.)
21,137.30
Sectoral MCap Rank
28
PB Ratio
(x)
3.60
Div Yield
(%)
0.00
Face Value
(₹)
1.00
Beta

Beta

1 Month-
3 Months-
6 Months-
1 Year-
3 Years-

-
VWAP
(₹)
1,849.17
52W H/L
(₹)
2,248.00 / 1,209.95

OneSource Specialty share price insights

  • Company's annual revenue growth of 647.84% outperformed its 3 year CAGR of 113.73%. (Source: Standalone Financials)

  • Company has spent 11.51% of its operating revenues towards interest expenses and 14.9% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • OneSource Specialty Pharma Ltd. share price moved down by -0.03% from its previous close of Rs 1,847.00. OneSource Specialty Pharma Ltd. stock last traded price is 1,846.60

    Share PriceValue
    Today/Current/Last1,846.60
    Previous Day1,847.001,848.65

InsightsOneSource Specialty

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    OneSource Specialty Share Price Returns

    1 Day-0.03%
    1 Week-2.29%
    1 Month0.32%
    3 Months-6.44%
    1 YearN.A.
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether OneSource Specialty belongs to analysts' top-rated companies list?

    View Stock Screeners

    OneSource Specialty Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    OneSource Specialty Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 4 Analysts

    Strong
    Sell
    SellHoldBuyStrong
    Buy
    • Target₹2049
    • OrganizationJM Financial
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy3222
    Buy1111
    Hold----
    Sell----
    Strong Sell----
    # Analysts4333

    OneSource Specialty Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 647.84% outperformed its 3 year CAGR of 113.73%. (Source: Standalone Financials)
      • Employee & Interest Expense

        Company has spent 11.51% of its operating revenues towards interest expenses and 14.9% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income332.54428.84397.96338.45296.28
      Total Income Growth (%)-22.467.7617.5814.23290.98
      Total Expenses309.46311.93418.64330.86300.85
      Total Expenses Growth (%)-0.79-25.4926.539.97215.05
      EBIT23.08116.91-20.687.60-4.57
      EBIT Growth (%)-80.26--372.26--
      Profit after Tax (PAT)-0.1998.50-68.85-42.08-5.55
      PAT Growth (%)-100.19----
      EBIT Margin (%)6.9427.26-5.202.24-1.54
      Net Profit Margin (%)-0.0622.97-17.30-12.43-1.87
      Basic EPS (₹)-0.028.61-6.31-3.89-1.34
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income326.27481.32341.76249.65244.03
      Total Income Growth (%)-32.2140.8436.902.31222.03
      Total Expenses274.42274.05370.87263.43268.22
      Total Expenses Growth (%)0.14-26.1140.79-1.79181.27
      EBIT51.85207.27-29.11-13.78-24.20
      EBIT Growth (%)-74.99----
      Profit after Tax (PAT)24.82174.19-73.02-57.89-23.97
      PAT Growth (%)-85.75----
      EBIT Margin (%)15.8943.06-8.52-5.52-9.91
      Net Profit Margin (%)7.6136.19-21.37-23.19-9.82
      Basic EPS (₹)2.1715.22-6.69-5.35-2.22
      Quarterly | Annual FY 2025
      Total Revenue1,462.33
      Total Revenue Growth (%)730.19
      Total Expenses1,418.55
      Total Expenses Growth (%)233.07
      Profit after Tax (PAT)-17.97
      PAT Growth (%)-
      Operating Profit Margin (%)14.54
      Net Profit Margin (%)-1.24
      Basic EPS (₹)-1.63
      Quarterly | Annual FY 2025 FY 2024 FY 2023
      Total Revenue1,317.27176.1441.41
      Total Revenue Growth (%)647.84325.41-68.60
      Total Expenses1,226.48425.90312.63
      Total Expenses Growth (%)187.9736.2334.89
      Profit after Tax (PAT)19.31-391.17-799.83
      PAT Growth (%)---
      Operating Profit Margin (%)19.42-93.24-577.76
      Net Profit Margin (%)1.48-227.52-2,065.99
      Basic EPS (₹)1.75-94.15-200.87

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025
      Total Assets7,550.24
      Total Assets Growth (%)476.97
      Total Liabilities1,669.66
      Total Liabilities Growth (%)82.90
      Total Equity5,880.58
      Total Equity Growth (%)1,386.07
      Current Ratio (x)0.98
      Total Debt to Equity (x)0.13
      Contingent Liabilities1,223.21
      Annual FY 2025 FY 2024 FY 2023
      Total Assets7,390.461,308.612,008.81
      Total Assets Growth (%)464.76-34.86-17.75
      Total Liabilities1,470.36912.901,223.36
      Total Liabilities Growth (%)61.06-25.38-14.44
      Total Equity5,920.10395.71785.45
      Total Equity Growth (%)1,396.07-49.62-22.42
      Current Ratio (x)0.960.280.26
      Total Debt to Equity (x)0.131.421.07
      Contingent Liabilities58.451,155.711,193.01

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025
      Net Cash flow from Operating Activities-67.85
      Net Cash used in Investing Activities-201.08
      Net Cash flow from Financing Activities412.01
      Net Cash Flow143.10
      Closing Cash & Cash Equivalent165.36
      Closing Cash & Cash Equivalent Growth (%)642.72
      Total Debt/ CFO (x)-11.37
      Annual FY 2025 FY 2024 FY 2023
      Net Cash flow from Operating Activities-47.28-107.21-162.88
      Net Cash used in Investing Activities-300.04510.55-67.72
      Net Cash flow from Financing Activities417.22-390.54118.32
      Net Cash Flow69.9012.79-112.28
      Closing Cash & Cash Equivalent92.0922.269.47
      Closing Cash & Cash Equivalent Growth (%)313.61135.00-92.22
      Total Debt/ CFO (x)-16.32-5.24-5.14

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025
      Return on Equity (%)-0.30
      Return on Capital Employed (%)3.26
      Return on Assets (%)-0.23
      Interest Coverage Ratio (x)2.91
      Asset Turnover Ratio (x)0.33
      Price to Earnings (x)-1,250.00
      Price to Book (x)3.40
      EV/EBITDA (x)42.30
      EBITDA Margin (%)33.49
      Annual FY 2025 FY 2024 FY 2023
      Return on Equity (%)0.32-98.85-101.83
      Return on Capital Employed (%)3.99-23.64-19.55
      Return on Assets (%)0.26-29.89-39.81
      Interest Coverage Ratio (x)2.39-0.94-3.32
      Asset Turnover Ratio (x)0.300.100.02
      Price to Earnings (x)1,111.11--
      Price to Book (x)3.38--
      EV/EBITDA (x)53.10--
      EBITDA Margin (%)29.77-48.86-408.10

    Financial InsightsOneSource Specialty

    • Income (P&L)
      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 647.84% outperformed its 3 year CAGR of 113.73%. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent 11.51% of its operating revenues towards interest expenses and 14.9% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    OneSource Specialty Share Price Forecast

    • Get multiple analysts’ prediction on OneSource Specialty

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on OneSource Specialty

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on OneSource Specialty

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    OneSource Specialty Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    OneSource Specialty Peer Comparison

    Peers InsightsOneSource Specialty

      Do you find these insights useful?

      • hate it

      • meh

      • love it

      OneSource Specialty Shareholding Pattern

      • Loading...
        Showing OneSource Specialty Shareholding as on Jun 2025
        CategoryJun 2025Mar 2025Dec 2024
        Promoters29.7934.2537.77
        Pledge25.0120.069.58
        FII18.6818.5417.44
        DII17.9617.9012.43
        Mutual Funds9.068.324.62
        Others33.5629.3132.35
      • Showing Shareholding as on Jun 2025
        CategoryNo. of SharesPercentage% Change QoQ
        Promoters3,40,96,19929.79 %-4.46
        Pledge85,26,38825.01 %4.95
        FII2,13,90,53818.68 %0.14
        DII2,05,67,88617.96 %0.06
        MF1,03,71,1309.06 %0.74
        Others3,84,11,39833.56 %4.25

      OneSource Specialty MF Ownership

      MF Ownership as on 30 September 2025

      OneSource Specialty Corporate Actions

      • Meeting DateAnnounced onPurposeDetails
        Sep 22, 2025Sep 01, 2025AGM-
        Aug 04, 2025Jul 29, 2025Board MeetingQuarterly Results
        Aug 01, 2025Jun 30, 2025POM-
        May 27, 2025Apr 25, 2025POM-
        May 05, 2025Apr 30, 2025Board MeetingAudited Results
      • Dividend announcements are not available.

      • No other corporate actions details are available.

      About OneSource Specialty

      OneSource Specialty Pharma Ltd., incorporated in the year 2007, is a Small Cap company (having a market cap of Rs 21,137.30 Crore) operating in Pharmaceuticals sector. OneSource Specialty Pharma Ltd. key Products/Revenue Segments include Sale of services and Pharmaceuticals for the year ending 31-Mar-2025. Show More

      • Executives

      • Auditors

      • AK

        Arun Kumar Pillai

        Chairperson & Non Executive Director
        NS

        Neeraj Sharma

        Managing Director & CEO
        BS

        Bharat Shah

        Non Executive Director
        CA

        Claudio Albrecht

        Ind. Non-Executive Director
        Show More
      • Deloitte Haskins & Sells

      Key Indices Listed on

      BSE Healthcare, BSE Select IPO, Nifty MidSmall Healthcare,

      Address

      Unit No. 902, Cyber One,Plot No - 4 & 6, Sector 30A, Vashi,Navi Mumbai, Sanpada,Thane, Maharashtra - 400703

      Trending in Markets

      Top Gainers As on 03:59 PM | 16 Oct 2025

      BLS Int. Services324.50
      45.95 (16.50%)
      Craftsman Automation6,800.50
      376.50 (5.87%)
      Oberoi Realty1,687.10
      85.70 (5.36%)
      Apar Industries8,784.50
      429.00 (5.14%)
      Ola Electric Mobilit55.38
      2.64 (4.99%)

      Top Losers As on 03:59 PM | 16 Oct 2025

      KEI Industries4,172.60
      -248.00 (-5.62%)
      Anant Raj633.35
      -29.20 (-4.41%)
      Netweb Technologies3,760.20
      -172.21 (-4.38%)
      Tata Investment906.00
      -35.00 (-3.72%)
      Max Financial1,552.40
      -56.70 (-3.53%)

      DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

      DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

      By using this site, you agree to the Terms of Service and Privacy Policy.

      The Economic Times